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Abstract
Background and Aim: Adalimumab is administered and dosed using a standardized
treatment regimen. Although therapeutic drug monitoring (TDM) may help optimize
treatment efficacy, the lower cut-off concentration of adalimumab needed to retain
disease remission has not been established. This cross-sectional study of patients with
Crohn’s disease on stable medication aimed to determine a lower therapeutic drug
concentration threshold of adalimumab associated with biochemical disease
remission.
Methods: C-reactive protein (CRP) and fecal calprotectin were used as established
markers and albumin as an explorative marker of disease activity. Time since intro-
duction, treatment interval, drug dosage, serum drug concentration and antidrug anti-
bodies, disease duration, age, and sex were recorded.
Results: The study included 101 patients who were divided into “active disease” and
“remission” groups for inflammatory markers based on cut-off levels of 5 mg/L for
CRP and 50 mg/kg for fecal calprotectin. Cut-off levels for albumin of 36.5 and
41.5 g/L were also added as further indicatives of remission. Receiver operating char-
acteristic analysis found optimal thresholds for adalimumab associated with remission
at 6.8–7.0 mg/L for the combination of CRP and fecal calprotectin and when combin-
ing CRP, fecal calprotectin, and albumin.
Conclusions: In patients with Crohn’s disease, serum adalimumab of at least
6.8 mg/L was associated with biochemical disease remission based on CRP and fecal
calprotectin, supporting the use of TDM to ensure disease control. Albumin should be
further tested in this setting.
Introduction
Crohn’s disease is a chronic inflammatory disease of the gastro-
intestinal tract that is characterized by transmural and discontinu-
ous inflammation of the intestinal wall. Common complications
of Crohn’s disease include strictures, fistulas, and abscesses, and
surgery is frequently required to address these complications.1,2
Over the last few decades, biological agents have emerged as a
pivotal treatment option in moderate to severe inflammatory
bowel disease.3 The fully humanized monoclonal antitumor
necrosis factor (TNF)-α agent adalimumab (ADL), which is
administered subcutaneously using a standardized treatment regi-
men, is well documented to induce and maintain disease remis-
sion in moderate to severe Crohn’s disease.4–6
Lack of response and loss of response represent major
challenges in anti-TNF-α treatment. Primary nonresponse,
defined as insufficient clinical response after induction therapy, is
reported in about one-third of the patients. Furthermore, even
after an initial treatment response, as many as half of all patients
experience a secondary loss of response at some point during the
maintenance phase.7 The concept of therapeutic drug monitoring
(TDM), which entails measuring serum drug concentrations and
antidrug antibodies (ADAs) in order to guide treatment, allows
an individualized approach to the dosing regimens of biologic
agents. TDM can provide the information needed to optimize
treatment and a better rationale for changing the treatment strat-
egy in patients with an inadequate response or a loss of response.
TDM thus has the potential to improve both drug efficacy and
drug safety.8–11
Even though TDM is increasingly available to clinicians
in everyday use, evidence regarding the therapeutic consequence
of TDM remains sparse and conflicting.12–16 An association
between serum ADL concentrations and disease activity has been
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reported, using lower therapeutic cut-off levels (in the range of
5–8 mg/L) to maintain treatment response/remission.12 However,
the optimal ADL serum concentration ranges in Crohn’s disease
are not yet firmly established.
In this study, we used C-reactive protein (CRP) and fecal
(f-) calprotectin (established markers) and serum albumin
(explorative marker) as distinct markers of inflammatory activity
in Crohn’s disease patients on maintenance treatment. We aimed
to identify a lower cut-off serum level associated with biochemi-
cal remission in ADL-treated patients.
Patients and methods
Patients and study design. This cross-sectional study,
which was conducted at Stavanger University Hospital, Sta-
vanger, Norway, included patients who were diagnosed with
Crohn’s disease and were at least 16 years old. The patients were
recruited from the outpatient clinic at the hospital. Included
patients were receiving maintenance treatment with ADL, with a
minimum of three doses administered before inclusion. The
patients had one study visit along with their regularly scheduled
trimonthly medical checkup from 1 April to 30 September 2014.
The exclusion criteria were inability to provide consent and
inability to adhere to the study protocol. The patients described
here belong to a larger IBD cohort, and some descriptive data
have been reported previously.17
Inflammatory markers. CRP and albumin concentrations
in blood were measured at the study visit and analyzed using the
CRP VARIO 6K2641 and Serum Albumin BCP (Bromocresol
purple), Architect c16000TM (Abbott Diagnostics, Lake Forest,
IL, USA); f-calprotectin was extracted from first morning defeca-
tion within 3 days before and 3 days after the study visit and was
quantified using the automated EliA Calprotectin 2 enzyme
fluoroimmunoassay (Phadia/Thermo-Fischer, Uppsala, Sweden).
Remission versus active disease was categorized biochem-
ically by CRP > 5 mg/L and/or f-calprotectin > 50 mg/kg.
Patients were consequently divided into an active disease group
and a remission group for each marker. These cut-off levels were
applied for analysis of ADL levels and for developing the
receiver operating characteristic (ROC) models. To optimize the
ROC model, we also used a combination of CRP and f-
calprotectin as a composite disease activity marker.
We also explored albumin as a surrogate marker for remis-
sion versus active disease. Based on albumin quartile analysis,
we selected two different cut-off values representing the limits
toward the lowest (36.5 g/L) and the highest (41.5 g/L) albumin
quartiles. We assumed that the lower albumin quartile levels
included the patients with the most severe inflammation, while
the upper albumin quartile levels represented the patients with
the least inflammatory burden. These albumin cut-offs were used
to develop two different explorative composite/combined ROC
models, including CRP, f-calprotectin, and albumin.
Serum drug concentrations and antidrug antibody
assay. Blood was drawn for the determination of serum con-
centrations of ADL and ADAs regardless of the injection time.
The drug was measured using a validated in-house assay in
which biotinylated recombinant TNF-α is used to trap ADL onto
a streptavidin-coated solid phase. The captured drug was then
quantified using an EU3+-labeled protein-A tracer and time-
resolved fluorescence. The assay for serum ADL concentrations
is fully automated on the AutoDELFIA® (PerkinElmer, Waltham,
MA, USA) immunoassay platform. ADAs to ADL were analyzed
using in-house inhibition assays that only measure neutralizing
ADAs (antibodies that inhibit the TNF-binding capacity of the
drugs).18 ADAs were not analyzed in samples with ADL serum
concentrations > 5 mg/L as high drug concentrations interfere
with the assays for ADAs.
Statistical analysis. The normality of the data was tested
using the Shapiro-Wilk test. Medians and ranges were reported
for continuous data as the data were not normally distributed.
The Mann–Whitney test was used to test for differences between
groups. Numbers and percentages were reported for categorical
data, and the chi-square test or Fisher’s exact test were used to
test for differences between groups as appropriate. To determine
the lower ADL cut-off concentrations, an ROC analysis was per-
formed separately for CRP, f-calprotectin, and for composite
models (with and without albumin), choosing the point closest to
the (0,1) corner (maximizing Youden’s index). Based on this, we
calculated the sensitivity, specificity, and area under the curve
(AUC) with standard error and 95% confidence intervals.
Associations between inflammatory markers and drug
levels were explored using multivariable regression analysis with
CRP, f-calprotectin (both log-transformed to conform to normal-
ity), and albumin as dependent variables in three different models
and serum adalimumab, age, and sex as independent variables.
For all statistical analyses, p < 0.05 was considered statistically
significant.
All analyses were conducted using SPSS, version
23 (IBM SPSS Statistics for Macintosh, IBM Corp., Armonk,
NY, USA) or GraphPad Prism, version 7 (GraphPad Software,
La Jolla, CA, USA).
Ethics. The study was approved by the regional ethics commit-
tee, REK Vest (2013/554/REK Vest; “IBD i Rogaland—en
tverrsnittstudie,” approved April 30, 2013), and was conducted
in compliance with the principles expressed in the Declaration of
Helsinki. All participating patients provided written informed
consent. The study was registered at Clinicaltrials.gov
(NCT02134054).
Results
Patients. The study included 101 of 108 eligible patients who
were on ADL maintenance treatment. The study lost one patient
to follow-up at another center, one patient was considered ineli-
gible for participation due to mental illness, and five patients
declined to participate.
The median age was 35 years, and 48 (47%) patients were
male. The median time since diagnosis was 9 years, and the
median duration of treatment with ADL was 32 months. In this
cohort, 16 (15.8%) patients had been on at least one other biolog-
ical agent before starting their current ADL treatment. Drug con-
centrations had been measured in roughly one-fifth of the
patients during the last 6 months prior to inclusion, and
13 (12.9%) patients used concomitant immunomodulators
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(CIMs). Ninety patients received a standardized treatment regi-
men for ADL (40 mg q2wk), 10 patients 40 mg weekly, and
1 patient 80 mg weekly (Table 1). The f-calprotectin results were
missing for 10 patients, and the serum albumin results were miss-
ing for 2 patients.
Serum drug concentrations. For all patients, the median
[range] drug concentration was 6.9 mg/L [0–24.6], with no sex
difference. There were no differences in drug concentrations
between patients who had been on previous biological medica-
tion versus those who had not (7.6 mg/L vs 6.8 mg/L, P = 0.63)
or between those who had measured drug concentrations before
inclusion versus those who had not (6.9 mg/L vs 6.8 mg/L,
P = 0.84). Use of CIMs versus no use of CIMs did not affect the
drug concentrations (6.7 mg/L vs 7.0 mg/L, P = 0.65).
Inflammatory markers. The median [range] values were as
follows: CRP, 2.9 mg/L [1–45]; f-calprotectin, 72 mg/kg [20–1250];
and albumin, 39.5 g/L [24.9–47.6]. The levels of the inflammatory
markers were not significantly influenced by previous exposure to
biologics, previous drug concentration measurement, or CIM use.
Associations between serum drug levels and
inflammatory markers. Three different multivariable
regression models using, respectively, CRP, f-calprotectin, and
albumin as dependent variables and serum ADL levels, age, and
sex as independent variables showed modest but significant nega-
tive associations between CRP and ADL levels (r2 = 0.10,
P = 0.002), between f-calprotectin and ADL levels (r2 = 0.16,
P < 0.005), and a positive association between albumin and ADL
levels (r2 = 0.14, P = 0.001) (Table 2).
Inflammatory markers and serum drug
concentrations
C-reactive protein. The patients were divided into two groups
based on CRP concentrations: 0–5 mg/L (remission, n = 71)
and > 5 mg/L (active disease, n = 30). These subgroups had sig-
nificantly different median [range] drug concentrations: 7.2 mg/L
[0–24.6] versus 6.0 mg/L [0–20], P = 0.04 (Fig. 1a).
f-Calprotectin. As for the CRP analysis, the patients were
divided into two subgroups based on f-calprotectin levels:
0–50 mg/kg (remission, n = 34) and > 50 mg/kg (active disease,
n = 57). These subgroups also had significantly different drug
concentrations: 8.9 mg/L [2.4–24.6] versus 6.4 mg/L [0–20],
P = 0.001 (Fig. 1b).
Composite variable of CRP and f-calprotectin. For the
combined variable of CRP and f-calprotectin, patients were
divided into two subgroups: CRP 0–5 mg/L and f-calprotectin
0–50 mg/kg (remission, n = 31) versus CRP > 5 mg/L and/or f-
calprotectin > 50 mg/kg (active disease, n = 60). The drug con-
centrations in these two groups were significantly different,
8.9 mg/L [2.4–24.6] versus 6.5 [0–20], P = 0.001 (Fig. 1c).
ROC analysis
C-reactive protein. Using a cut-off level of 5 mg/L for CRP with
values > 5 mg/L representing active disease, an ROC analysis gave
an AUC of 0.63 (std. error 0.062, P = 0.04, 95% CI 0.51–0.75). In
Table 1 Baseline characteristics
Variable
Age (years) 35 (16–78)
Male, n (%) 48 (47%)
Time since diagnosis (years) 9 (0–36)
Duration of treatment (months) 32 (2–112)
SDC (mg/L) 6.9 (0–24.6)
CRP (mg/L) 2.9 (1–45)
f-Calprotectin (mg/kg) 72 (20–1250)
Albumin (g/L) 39.5 (24.9–47.6)
HBI 2 (0–11)
Disease distribution, n (%)
Upper GI (L4) 1 (1.0%)
Ileal (L1) 42 (41.6%)
Colonic (L2) 19 (18.8%)
Ileocolonic (L3) 39 (38.6%)
Phenotype, n (%)
Nonstricturing, nonpenetrating (B1) 82 (81.2%)
Stricturing (B2) 8 (7.9%)
Penetrating/Perianal disease (B3) 11 (10.9%)
Previous exposure to biologics, n (%) 16 (15.8%)
SDC 6 months prior to inclusion, n (%) 15 (14.9%)
Detectable ADAs, n (%) 7 (6.9%)





Smoking status, n (%)
Current 19 (18.8%)
Previous 21 (20.8%)
Values are absolute numbers or medians (ranges).
ADA, antidrug antibodies; CRP, C-reactive protein; F-calprotectin, fecal
calprotectin; HBI, Harvey-Bradshaw Index; SDC, serum drug
concentration.
Table 2 Age- and gender-adjusted regression analyses for serum adalimumab
CRP Fecal calprotectin Albumin
β P-value R2 β P-value R2 β P-value R2
Adalimumab −0.06 0.002 0.10 −0.08 <0.0005 0.16 0.27 0.001 0.14
Age 0.002 0.80 −0.01 0.32 −0.04 0.17
Sex −0.20 0.50 −0.21 0.35 −1.20 0.13
CRP, C-reactive protein.
Adalimumab lower cut-off Crohn’s disease A Carlsen et al.
412 JGH Open: An open access journal of gastroenterology and hepatology 4 (2020) 410–416
© 2019 The Authors. JGH Open: An open access journal of gastroenterology and hepatology published by Journal of Gastroenterology and Hepatology Foundation and
John Wiley & Sons Australia, Ltd.
terms of optimizing sensitivity and specificity, the optimal lower
cut-off value for therapeutic serum concentration was 5.7 mg/L, with
a sensitivity of 70% and a specificity of 50% (Fig. 2a).
f-calprotectin. We used a cut-off level of 50 mg/kg for f-
calprotectin, with values > 50 mg/kg representing active disease.
An ROC analysis gave an AUC of 0.71 (std. error 0.05,
P < 0.001, 95% CI 0.61–0.82). In terms of optimizing sensitivity
and specificity, the optimal lower cut-off value for therapeutic
serum concentration was 6.9 mg/L, with a sensitivity of 71% and
a specificity of 58% (Fig. 2b).
Composite variable of CRP and f-calprotectin. An ROC
analysis gave an AUC of 0.71 (std. error 0.06, P = 0.001, 95%
CI 0.60–0.82). In terms of optimizing sensitivity and specificity,
the optimal lower cut-off value for therapeutic serum concentra-
tion was 6.8 mg/L, with a sensitivity of 74% and a specificity of
57% (Fig. 2c).
Albumin
ROC analysis of composite variable CRP, f-calprotectin,
and albumin. Serum albumin quartile levels were as follows:
Q1: 24.9–36.4 g/L; Q2: 36.5–39.5 g/L; Q3: 39.6–41.4 g/L; and
Q4: 41.5–47.6 g/L.
Two models were developed according to the different
selected albumin cut-off levels.
Adding albumin ≥ 36.5 g/L to CRP 0–5 mg/L and f-
calprotectin 0–50 mg/kg, an ROC analysis gave an AUC of 0.72
A B C
Figure 1 Adalimumab concentrations (mg/L) in patients with Crohn’s disease with (a) C-reactive protein (CRP) 0–5 mg/L (remission, n = 71),
CRP > 5 mg/L (active disease, n = 30). (b) Fecal calprotectin 0–50 mg/kg (remission, n = 34), fecal calprotectin > 50 mg/kg (active disease, n = 57).
(c) CRP 0–5 mg/L and fecal calprotectin 0–50 mg (remission, n = 31), CRP > 5 mg/L and/or fecal calprotectin > 50 mg/kg (active disease, n = 60).
Medians and ranges are shown.
A B C
Figure 2 Receiver operating characteristic (ROC) curve analysis of adalimumab concentrations in (a) Patients with C-reactive protein (CRP)
> 5 mg/L representing active disease. (b) Patients with fecal calprotectin > 50 mg/kg representing active disease. (c) Patients with and without
CRP > 5 mg/L and/or fecal calprotectin > 50 mg/kg representing active disease. AUC, area under the curve.
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(std. error 0.06, P = 0.002, 95% CI 0.61–0.84). In terms of opti-
mizing sensitivity and specificity, the optimal lower cut-off value
for therapeutic serum concentration was 6.8 mg/L, with a sensi-
tivity of 77% and a specificity of 56% (Fig. 3a).
For albumin ≥ 41.5 g/L, a composite ROC analysis gave
an AUC of 0.71 (std. error 0.08, P = 0.01, 95% CI 0.56–0.86).
In terms of optimizing sensitivity and specificity, the optimal
lower cut-off value for therapeutic serum concentration was
7.0 mg/L, with a sensitivity of 71% and a specificity of 53%
(Fig. 3b).
Discussion
In this study, we determined a lower ADL cut-off concentration
of 6.8 mg/L to be associated with biochemical remission in
Crohn’s disease, using CRP and f-calprotectin as a composite
surrogate disease activity marker. Similarly, using separate
inflammatory marker models, we found cut-off concentrations of
5.7 mg/L and 6.9 mg/L for CRP and f-calprotectin, respectively.
In two exploratory composite models, we also added serum albu-
min to CRP and f-calprotectin, showing lower thresholds of
6.8 mg/L (using albumin cut-off ≥ 36.5 g/L) and 7.0 mg/L (using
albumin cut-off ≥ 41.5 g/L). Thus, we demonstrated separate cut-
off values for ADL concentrations that were statistically signifi-
cant using all three inflammation markers; dividing patients
based on their levels of the selected disease activity marker
appeared to be useful for developing ROC models. The signifi-
cant associations between ADL and investigated disease activity
markers supported these findings.
Previous studies have also used conventional biomarkers
of inflammation in Crohn’s disease to examine ADL concentra-
tion thresholds with the aim of identifying the lowest drug con-
centration required to maintain disease remission. CRP has been
widely used as such a biomarker,19–22 and studies have demon-
strated an association between CRP normalization and ADL con-
centrations, finding lower cut-off levels in the range of
5.6–8.5 mg/L.23–27 These results are in line with our findings.
The f-calprotectin protein is another well-documented
marker of disease activity in Crohn’s disease.28–31 One previous
study found a lower ADL threshold of 7.2 mg/L using f-
calprotectin levels of 59 mg/kg as indicative of active disease.27
Both the f-calprotectin level used and the lower ADL cut-off
determined are in line with our results.
Only one previous study explored a combined disease activ-
ity marker of CRP (< 5 mg/L) and f-calprotectin (< 250 mg/kg),
determining a lower ADL cut-off of at least 9.5 mg/L. However,
the referred study only consisted of 34 patients, and the result did
not reach statistical significance (P = 0.44).32
Serum albumin levels have not been widely used as a
marker of disease activity in Crohn’s disease. However, an associ-
ation has been reported,33–35 and one study showed an association
between ADL concentrations and albumin levels (albumin levels <
40 g/L were considered indicative of active disease), with a lower
ADL cut-off level of 7.0 mg/L.26 Our experimental composite var-
iable consisting of CRP, f-calprotectin, and serum albumin yielded
concurrent ADL cut-offs of 6.8 mg/L and 7.0 mg/L. This compos-
ite model also produced the highest AUC, although it was only
slightly improved compared with the uni- and bivariate models.
The patients in this study had a considerable disease duration
(median of 9 years) and were on long-term maintenance treatment
(median duration of 32 months). Thus, the majority of patients
were probably enduring responders with low or no disease activity
as reflected by their low median concentrations of CRP and f-
calprotectin. Interestingly, we were still able to define a lower cut-
off concentration of ADL that distinguished between remission
and active disease. This indicates that proactive monitoring of
ADL concentrations in clinical practice could be meaningful to
retain remission in the long-term follow-up of patients with
Crohn’s disease, not only after commencing ADL therapy.
Although it is difficult to make direct comparisons
between the ADL thresholds in our study and in previous reports
due to differences in the serum drug assays and the methodology,
as well as in the ROC curve analysis (AUC) and in the selection
of specificity and sensitivity, there are still consistent similarities
with our threshold findings in the range of 5.8–7.0 mg/L.
A B
Figure 3 Receiver operating characteristic (ROC) curve analysis of adalimumab concentrations in (a) Patients with C-reactive protein (CRP)
> 5 mg/L and fecal calprotectin > 50 mg/kg and albumin < 36.5 g/L representing active disease. (b) Patients with CRP > 5 mg/L and fecal
calprotectin > 50 mg/kg and albumin < 41.5 g/L representing active disease. AUC, area under the curve.
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On the other hand, one recent study using a CRP level of
5 mg/L reported a considerably higher ADL threshold of
11.8 mg/L.36 This could be explained by more severe disease
(i.e. a higher frequency of fistulizing disease, as well as high-
dose treatment) in that patient population.
A strength of our study was the large sample size of
101 patients, making it larger than previous studies. This study
also has some limitations, including its cross-sectional design.
We did not perform colonoscopies to investigate endoscopic
inflammation, so the true rate of remission, that is, mucosal
healing, was therefore unknown. Blood samples to analyze ADL
concentrations were drawn randomly during the treatment inter-
val. Although ADL levels appear to be stable at different time
points between injections,27,37,38 one study suggested that ADL
levels are lower at the end of treatment cycles, favoring the use
of true trough measurements for ADL.39 Finally, although the
ROC analyses yielded significant AUCs, this method has some
degree of uncertainty, including extrapolation of the ROC curve
and the model used for curve fitting.
In conclusion, CRP and f-calprotectin may be useful
markers of clinical disease activity in order to identify a lower
ADL threshold. Serum albumin appears to be a promising marker
in this setting but needs further validation. A serum ADL con-
centration of at least 6.8 mg/L appears favorable for maintaining
biochemical remission in Crohn’s disease, supporting a proactive
role of TDM in Crohn’s disease patients on ADL treatment.
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